Bladder Cancer - Results from #20

Critical shortage in BCG immunotherapy: How did we get here and where will it take us? November 16, 2021

CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin November 15, 2021

Dramatic Impact of Centralization and a Multidisciplinary Bladder Cancer Program in Reducing Mortality: The CABEM Project November 15, 2021

Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities. November 15, 2021

Evaluating health-related quality of life as a prognostic tool for overall survival in routine cancer care for older patients with bladder cancer: A US based study. November 15, 2021

Safety, Efficacy and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. November 15, 2021

Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. November 12, 2021

Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. November 12, 2021

Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. November 11, 2021

Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression. November 11, 2021

The Role of RAF1 Amplifications as Drivers of a Subset of Bladder Cancers - Expert Commentary November 10, 2021

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. November 10, 2021

The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial. November 10, 2021

Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021. November 10, 2021

Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. November 10, 2021

Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results. November 9, 2021

Bladder cancer histological variants: which parameters could predict the concordance between transurethral resection of bladder tumor and radical cystectomy specimens? November 9, 2021

Urobiome: An outlook on the metagenome of urological diseases. November 8, 2021

A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. November 8, 2021

Prognostic value of preoperative neutrophil-to-lymphocyte ratio in histological variants of non-muscle-invasive bladder cancer. November 8, 2021

Page 2 of 412

email news signup